Great Expectations for CPhI Worldwide 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Great Expectations for CPhI Worldwide 2012



This year’s CPhI Worldwide event is set to take place at the Feria de Madrid in Spain, October 9–12, with expectations for more than 30,000 visitors and 2200 exhibitors from 140 countries. Despite the continuing troubled economic times, the show continues to boast growth; 108 new companies are preparing to join the many returning exhibitors, while the number of exhibitors in the ICSE logistics and supply chain zone will double compared with 2011. Indeed, this year will see the highest number of exhibitors compared with any previous year.

Recently, the organisers of CPhI, UBM, have been introducing a zoning structure to many of their events and this format will be present in Madrid to help facilitate navigation. The zones featured will be:

  • CPhI Worldwide: APIs; Generic APIs; Custom Manufacturing; Fine Chemicals; Intermediates; Excipients/Formulations; Biopharmaceuticals; General
  • ICSE: Logistics and Supply Chain; BioServices; Analytical & Lab Services; Pre Clinical Trials, Clinical Trials Stages 1-4, CRO, Clinical Data Management Zone; Trial Stages; New Exhibitors; North America Zone; General Floor
  • P-MEC Europe: LABWorld
  • InnoPack: Labelling

In addition, the events will be divided into global pavilions to help visitors quickly locate suppliers from specific regions. The pavilions will feature Argentina, Brazil, China, Egypt, France, India, Ireland, Korea, Morocco, North America, Portugal, Scotland and the UK. Madrid will also see the introduction of pavilions for Russia and Malaysia.

The 2012 event will also see an expansion of the CPhI Innovation Awards, which are being rebranded as the CPhI Pharma Awards for 2012. In addition, the Innovation award category has been expanded to look at showcasing exhibitors with groundbreaking innovations in formulation, drug delivery, chemical manufacturing of APIs and intermediates, and biomanufacturing of biopharmaceuticals and intermediates. You can find out more about the awards here.

The Pharmaceutical Technology and Pharmaceutical Technology Europe teams will be in attendance at the show in Hall 10, Stand A23. We look forward to meeting with you and hearing your thoughts about the show.

You can read all of CPhI news here.

CPhI was held in Madrid for the first time in 2009. Did you attend? What did you think of the location? And are you happy that the show is returning to Madrid? Let me know your thoughts in a comment!

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search

Click here